NCT05996458 A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors
| NCT ID | NCT05996458 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Digestive Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 84,000 participants |
| Start Date | 2023-08-01 |
| Primary Completion | 2032-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 84,000 participants in total. It began in 2023-08-01 with a primary completion date of 2032-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer
Eligibility Criteria
Inclusion Criteria: * 1\. Subjects were 45 to 70 years old when enrolled 2. Willing and able to sign informed consent Exclusion Criteria: * 1\. History of any type of malignancy 2. Previous resection of esophagus, stomach or colorectal 3. Received gastrointestinal endoscopy such as colonoscopy and gastroscopy in recent 5 years 4. Have received fecal occult blood test and fecal DNA test in the past 1 year. 5. Contraindications to endoscopy. 6. Warning symptoms of digestive tract tumors, including: 1. Difficulty swallowing, choking or halting feeling when eating recently 2. Recent esophageal foreign body sensation or swallowing pain 3. Recent long-term loss of appetite and appetite 4. Recent and prolonged symptoms of indigestion (including acid reflux, heartburn, abdominal grumbling, burping, nausea or premature satiety, etc.) 5. Recent symptoms of abdominal mass, abdominal pain, vomiting or hematemesis 6. It was medically diagnosed as iron deficiency anemia 7. Recent changes in hematochezia, black stool or stool character and frequency 8. Recent symptoms of perianal discomfort (including soreness, itching, lumps, prolapse or other discomfort) 9. Unexplained weight loss (more than 10% of base body weight) in the past 6 months Step 7 Get pregnant 8. There are other serious comorbiditions that reduce screening benefits (including severe lung disease, advanced kidney disease, advanced liver disease, severe heart failure, etc.)
Contact & Investigator
Kaichun Wu
STUDY CHAIR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT05996458 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 70 Years, studying Digestive Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05996458 currently recruiting?
Yes, NCT05996458 is actively recruiting participants. Contact the research team at zhengrong4956@163.com for enrollment information.
Where is the NCT05996458 trial being conducted?
This trial is being conducted at Zhaoqing, China.
Who is sponsoring the NCT05996458 clinical trial?
NCT05996458 is sponsored by Xijing Hospital. The principal investigator is Kaichun Wu at Xijing Hospital. The trial plans to enroll 84,000 participants.